22 Humanized NOG-EXL mice exhibit improved overall survival and less severe myeloid cell activation relative to humanized NSG-SGM3 mice
BackgroundEngraftment efficiency of human immune cell lineages in super immunodeficient mice varies, and numerous strains have been developed to improve reconstitution of humanized immune system mice. NSG-SGM3 and NOG-EXL mice combine severe immunodeficiency with transgenic expression of human myelo...
Uložené v:
| Vydané v: | Journal for immunotherapy of cancer Ročník 11; číslo Suppl 1; s. A24 |
|---|---|
| Hlavní autori: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BMJ Publishing Group Ltd
01.11.2023
BMJ Publishing Group LTD BMJ Publishing Group |
| Predmet: | |
| ISSN: | 2051-1426 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | BackgroundEngraftment efficiency of human immune cell lineages in super immunodeficient mice varies, and numerous strains have been developed to improve reconstitution of humanized immune system mice. NSG-SGM3 and NOG-EXL mice combine severe immunodeficiency with transgenic expression of human myeloid stimulatory cytokines, resulting in improved expansion of myeloid populations. However, humanized NSG-SGM3 (huNSG-SGM3) mice develop a lethal macrophage activation syndrome (MAS) and mast cell hyperplasia that limit their use in long-term studies, especially those requiring humanization followed by tumor xenotransplantation. It is currently unclear to what extent humanized NOG-EXL (huNOG-EXL) mice suffer from the same conditions observed in huNSG-SGM3 mice. In this study, we aimed to compare the effects of human CD34+ hematopoietic stem cell engraftment in these two mouse strains in an orthotopic glioblastoma patient-derived organoid xenograft model.MethodsNSG-SGM3 mice (n=10) humanized in-house were compared to both NOG-EXL mice (n=10) humanized in-house and to commercially available huNOG-EXL mice (n=12). Mice were euthanized at humane or study endpoints, and a complete pathological assessment was performed. A semiquantitative multiparametric clinicopathological scoring system was developed to characterize the myeloid proliferative disorder.ResultsBoth the NOG-EXL mice humanized in-house and commercially available huNOG-EXL mice survived longer (to experimental endpoint) than huNSG-SGM3 mice (22 vs 17 weeks post engraftment), with significantly less severe MAS and lack of mastocytic proliferation. Major findings included mast cell infiltration of the pancreas and liver (huNSG-SGM3 only), increased eosinophilopoiesis, anemia, and histiocytic infiltration of the spleen (both strains). Engraftment of human lymphocytes, assessed by immunohistochemistry, was similar in the two strains. The longer survival and decreased MAS severity in NOG-EXL mice enabled their use in a patient-derived xenograft transplantation study.ConclusionsHumanized NOG-EXL mice develop a milder myeloid activation syndrome and do not develop mast cell hyperplasia relative to humanized NSG-SGM3 mice. Thus, the NOG-EXL model may be better suited than the NSG-SGM3 model for immuno-oncology studies requiring long-term survival post humanization. Future directions include further assessment of the lymphocyte populations in both strains and application of the humanized NOG-EXL for patient-derived xenograft models.AcknowledgementsThe authors thank the staff of the Penn Vet Histology Lab and the Penn Stem Cell and Xenograft Core for technical assistance.Ethics ApprovalAll the mice included in this study were maintained by the Stem Cell and Xenograft Core at the University of Pennsylvania under the protocol #803506 which has been reviewed and approved by the Institutional Animal Care and Use Committee (IACUC). The participant gave informed consent for use of glioblastoma patient-derived organoids, under protocol #832366, approved by the University of Pennsylvania Institutional Review Board (IRB). |
|---|---|
| AbstractList | BackgroundEngraftment efficiency of human immune cell lineages in super immunodeficient mice varies, and numerous strains have been developed to improve reconstitution of humanized immune system mice. NSG-SGM3 and NOG-EXL mice combine severe immunodeficiency with transgenic expression of human myeloid stimulatory cytokines, resulting in improved expansion of myeloid populations. However, humanized NSG-SGM3 (huNSG-SGM3) mice develop a lethal macrophage activation syndrome (MAS) and mast cell hyperplasia that limit their use in long-term studies, especially those requiring humanization followed by tumor xenotransplantation. It is currently unclear to what extent humanized NOG-EXL (huNOG-EXL) mice suffer from the same conditions observed in huNSG-SGM3 mice. In this study, we aimed to compare the effects of human CD34+ hematopoietic stem cell engraftment in these two mouse strains in an orthotopic glioblastoma patient-derived organoid xenograft model.MethodsNSG-SGM3 mice (n=10) humanized in-house were compared to both NOG-EXL mice (n=10) humanized in-house and to commercially available huNOG-EXL mice (n=12). Mice were euthanized at humane or study endpoints, and a complete pathological assessment was performed. A semiquantitative multiparametric clinicopathological scoring system was developed to characterize the myeloid proliferative disorder.ResultsBoth the NOG-EXL mice humanized in-house and commercially available huNOG-EXL mice survived longer (to experimental endpoint) than huNSG-SGM3 mice (22 vs 17 weeks post engraftment), with significantly less severe MAS and lack of mastocytic proliferation. Major findings included mast cell infiltration of the pancreas and liver (huNSG-SGM3 only), increased eosinophilopoiesis, anemia, and histiocytic infiltration of the spleen (both strains). Engraftment of human lymphocytes, assessed by immunohistochemistry, was similar in the two strains. The longer survival and decreased MAS severity in NOG-EXL mice enabled their use in a patient-derived xenograft transplantation study.ConclusionsHumanized NOG-EXL mice develop a milder myeloid activation syndrome and do not develop mast cell hyperplasia relative to humanized NSG-SGM3 mice. Thus, the NOG-EXL model may be better suited than the NSG-SGM3 model for immuno-oncology studies requiring long-term survival post humanization. Future directions include further assessment of the lymphocyte populations in both strains and application of the humanized NOG-EXL for patient-derived xenograft models.AcknowledgementsThe authors thank the staff of the Penn Vet Histology Lab and the Penn Stem Cell and Xenograft Core for technical assistance.Ethics ApprovalAll the mice included in this study were maintained by the Stem Cell and Xenograft Core at the University of Pennsylvania under the protocol #803506 which has been reviewed and approved by the Institutional Animal Care and Use Committee (IACUC). The participant gave informed consent for use of glioblastoma patient-derived organoids, under protocol #832366, approved by the University of Pennsylvania Institutional Review Board (IRB). |
| Author | Radaelli, Enrico Verrelle, Jillian Binder, Zev Skuli, Nicolas Tarrant, James C Willis, Elinor Banerjee, Esha Assenmacher, Charles-Antoine Jacobson, Moriah L |
| Author_xml | – sequence: 1 givenname: Elinor surname: Willis fullname: Willis, Elinor organization: University of Pennsylvania, Philadelphia, PA, USA – sequence: 2 givenname: Jillian surname: Verrelle fullname: Verrelle, Jillian organization: University of Pennsylvania, Philadelphia, PA, USA – sequence: 3 givenname: Esha surname: Banerjee fullname: Banerjee, Esha organization: University of Pennsylvania, Philadelphia, PA, USA – sequence: 4 givenname: Charles-Antoine surname: Assenmacher fullname: Assenmacher, Charles-Antoine organization: Comparative Pathology Core, Department of Pathobiology, School of Veterinary Medicine at the University of Pennsylvania, Philadelphia, PA, USA – sequence: 5 givenname: James C surname: Tarrant fullname: Tarrant, James C organization: GlaxoSmithKline, Collegeville, PA, USA – sequence: 6 givenname: Nicolas surname: Skuli fullname: Skuli, Nicolas organization: University of Pennsylvania, Philadelphia, PA, USA – sequence: 7 givenname: Moriah L surname: Jacobson fullname: Jacobson, Moriah L organization: Taconic Biosciences, Rockville, MD, USA – sequence: 8 givenname: Zev surname: Binder fullname: Binder, Zev organization: University of Pennsylvania, Philadelphia, PA, USA – sequence: 9 givenname: Enrico surname: Radaelli fullname: Radaelli, Enrico organization: Comparative Pathology Core, Department of Pathobiology, School of Veterinary Medicine at the University of Pennsylvania, Philadelphia, PA, USA |
| BookMark | eNpFkcFO3DAQhq2qlUopz1BLnEPtsWM7R7Siy0rbclgq9WY58WxxlMTUya6AUy899DV5EhwWxMUeeX79v2e-T-T9EAck5AtnZ5wL9bUNU1MAA1FsVteLuThjDOAdOQJW8oJLUB_JyTi2jDHOhDDGHJH_AI9__13uejeEB_T0x9WyuPi1pn1okOLdTajDREN_m-I-d_ORXNfRcZf2Ye866gZPOxxHOmJuIe3vsYvB0wazyjVTFk0hDjRhl4s90inSm7ewzbLYLL-L57TP5MPWdSOevNzH5Oe3i-vFZbG-Wq4W5-ui5kZD4T1vpJSmVoYDlKr2YKRGqfJAzDMFZVOyWrEKjHGce6W1MZVWfqudw9KLY7I6-ProWnubQu_SvY0u2OeHmH5bl6bQdGiVNzUTTBoPWwkVr0AoDd4ZKVBXGrLX6cEr7-fPDsfJtnGXhvx9m-NNCYqbWSUOqrpv3wSc2RmbnbHZmZZ9xWZnbOIJgkmO8A |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 9YT ACMMV K9. DOA |
| DOI | 10.1136/jitc-2023-SITC2023.0022 |
| DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access ProQuest Health & Medical Complete (Alumni) DOAJ Directory of Open Access Journals |
| DatabaseTitle | ProQuest Health & Medical Complete (Alumni) |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ: Directory of Open Access Journal (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2051-1426 |
| EndPage | A24 |
| ExternalDocumentID | oai_doaj_org_article_6d8b03048d2f4291923672da843e7972 jitc |
| GroupedDBID | 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABUWG ACGFS ACMMV ADBBV ADRAZ ADUKV AFKRA AHBYD AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK EBS EJD FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 M~E OK1 PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RMJ ROL RPM RSV SOJ UKHRP K9. PHGZM PJZUB PPXIY AFFHD |
| ID | FETCH-LOGICAL-b1872-dd1c4448b6812256bd2847e463380d0625c50b609288a11d67788976df7aae5d3 |
| IEDL.DBID | DOA |
| IngestDate | Mon Nov 10 04:31:23 EST 2025 Tue Oct 07 06:46:18 EDT 2025 Thu Apr 24 22:49:48 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Suppl 1 |
| Language | English |
| License | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b1872-dd1c4448b6812256bd2847e463380d0625c50b609288a11d67788976df7aae5d3 |
| Notes | SITC 38th Annual Meeting (SITC 2023) Abstracts Biomarkers, Immune Monitoring and Novel Technologies ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
| OpenAccessLink | https://doaj.org/article/6d8b03048d2f4291923672da843e7972 |
| PQID | 2888526182 |
| PQPubID | 2040222 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6d8b03048d2f4291923672da843e7972 proquest_journals_2888526182 bmj_journals_10_1136_jitc_2023_SITC2023_0022 |
| PublicationCentury | 2000 |
| PublicationDate | 20231100 20231101 2023-11-01 |
| PublicationDateYYYYMMDD | 2023-11-01 |
| PublicationDate_xml | – month: 11 year: 2023 text: 20231100 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | Journal for immunotherapy of cancer |
| PublicationTitleAbbrev | J Immunother Cancer |
| PublicationYear | 2023 |
| Publisher | BMJ Publishing Group Ltd BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: BMJ Publishing Group Ltd – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| SSID | ssj0001033888 |
| Score | 2.2364209 |
| Snippet | BackgroundEngraftment efficiency of human immune cell lineages in super immunodeficient mice varies, and numerous strains have been developed to improve... |
| SourceID | doaj proquest bmj |
| SourceType | Open Website Aggregation Database Publisher |
| StartPage | A24 |
| SubjectTerms | Hyperplasia Immunotherapy Regular and Young Investigator Award Abstracts Stem cells |
| Title | 22 Humanized NOG-EXL mice exhibit improved overall survival and less severe myeloid cell activation relative to humanized NSG-SGM3 mice |
| URI | https://jitc.bmj.com/content/11/Suppl_1/A24.full https://www.proquest.com/docview/2888526182 https://doaj.org/article/6d8b03048d2f4291923672da843e7972 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral databaseCode: RBZ dateStart: 20130101 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://www.biomedcentral.com/search/ omitProxy: false ssIdentifier: ssj0001033888 providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ: Directory of Open Access Journal (DOAJ) databaseCode: DOA dateStart: 20130101 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://www.doaj.org/ omitProxy: false ssIdentifier: ssj0001033888 providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources (ISSN International Center) databaseCode: M~E dateStart: 20130101 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://road.issn.org omitProxy: false ssIdentifier: ssj0001033888 providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection (ProQuest) databaseCode: 7X7 dateStart: 20130501 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://search.proquest.com/healthcomplete omitProxy: false ssIdentifier: ssj0001033888 providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central Database Suite (ProQuest) databaseCode: BENPR dateStart: 20130501 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://www.proquest.com/central omitProxy: false ssIdentifier: ssj0001033888 providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database databaseCode: PIMPY dateStart: 20130501 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: http://search.proquest.com/publiccontent omitProxy: false ssIdentifier: ssj0001033888 providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF5BQYhLVSiI0BLtgSOr2mtnd32kVZpWIiEirRROq30KV2mCErcSnHrpgb_JL2Fm7aqVOHDhZnsPY8-M57U78xHyvlChqkyumLDBslJKyyrlOIsF9nVaZ9wgJrAJOZmo-byaPoD6wjNh7XjglnEHwiuL23fK8wi2EwMSIbk3qiyCrGSyvpmsHiRTqbqSQeqlVHegKy_EwUXdOIZY4Wx2enaEF1hL4eBS7OVFN7D_L3ucnMzxDtnuokP6sX2rF-RRWL4kz8bd_vcu-cX575vbVHivfwZPJ59HbDj_RBFTngbEuq4bWqc6Aazi6UyzWNDNFdgD0Chqlp4uwLRRcIdhHejlj7BY1Z5i9Z5ih0Nbn6Vtg8t1oM2KfrsnNhux2WhcJGqvyPnx8OzohHVgCszmSnLmfe5KyMUsDhyDOMd6dEyhFMCozGeQBrlBZkVWcaVMnnscLKcgVvFRGhMGvnhNtparZXhDKATlhXMihsrHsozc5iZEWWbKCSeViD3yAXiqu59ho1OeUQiNItDIeX0nAo0i6JFDZL7-3o7X0DjwOj0ANdCdGuh_qUGP7N-J7p4wfIoaQIqo-Nv_QWOPPE8KlDoR98lWs74K78hTd93Um3WfPJZz2SdPDoeT6Zd-Uke4m56Op1__ABeu4DA |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=22%E2%80%85Humanized+NOG-EXL+mice+exhibit+improved+overall+survival+and+less+severe+myeloid+cell+activation+relative+to+humanized+NSG-SGM3+mice&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Willis%2C+Elinor&rft.au=Verrelle%2C+Jillian&rft.au=Banerjee%2C+Esha&rft.au=Charles-Antoine+Assenmacher&rft.date=2023-11-01&rft.pub=BMJ+Publishing+Group+LTD&rft.eissn=2051-1426&rft.volume=11&rft.issue=Suppl+1&rft.spage=A24&rft.epage=A24&rft_id=info:doi/10.1136%2Fjitc-2023-SITC2023.0022&rft.externalDBID=HAS_PDF_LINK |